{"product_id":"vnda-bcg-matrix","title":"(VNDA) Vanda Pharmaceuticals Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Vanda Pharmaceuticals Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHETLIOZ rare sleep-disorder franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHETLIOZ is Vanda Pharmaceuticals Inc.’s clearest Stars asset: it is FDA-approved for non-24-hour sleep-wake disorder, a rare condition that affects about 50% to 80% of totally blind people. Orphan status helps support premium pricing and tight, specialist prescribing. Label expansion could widen the base beyond one niche and keep this franchise Vanda’s main growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFanapt long-acting injectable schizophrenia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFanapt long-acting injectable targets schizophrenia’s big adherence gap, where about 40% to 60% of patients stop oral antipsychotics. Long-acting injectables are still a growth niche in CNS, and they can cut relapse and rehospitalization costs. If Vanda Pharmaceuticals Inc. wins the launch, it adds a higher-growth layer to Fanapt and becomes a major upside driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTradipitant gastroparesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTradipitant targets gastroparesis, a GI market with high unmet need and few approved options, so even modest efficacy can matter. Late-stage data could support fast share gains because patients still face nausea, vomiting, and poor quality of life. In Vanda Pharmaceuticals Inc.'s BCG Matrix, it fits a high-growth pipeline bet with Star potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVTR-297 hematologic malignancies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVTR-297 in hematologic malignancies sits in a high-spend oncology lane; global oncology drug sales are already above $200 billion, so even a small share can matter. Blood cancers also support premium pricing when response data are strong, because relapse and chronic use can lift lifetime value. If Vanda Pharmaceuticals Inc. shows clear differentiation, this asset could reach a much larger commercial pool than a niche CNS program. That makes it a real star candidate, but only if late-stage data hold up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge oncology spend pool\u003c\/li\u003e\n\u003cli\u003ePremium pricing possible\u003c\/li\u003e\n\u003cli\u003eBroader commercial reach\u003c\/li\u003e\n\u003cli\u003eStar if data succeed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVQW-765 psychiatric disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVQW-765 fits a large psychiatry market, where chronic disorders like depression, schizophrenia, and bipolar disorder drive recurring treatment. If it shows strong safety and efficacy, adoption could be fast because clinicians switch quickly in high-unmet-need CNS space. For Vanda Pharmaceuticals Inc., it remains one of the clearest growth options in the portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge recurring CNS demand\u003c\/li\u003e\n\u003cli\u003eHigh unmet need supports uptake\u003c\/li\u003e\n\u003cli\u003eBest-in-class data could accelerate use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVanda’s Star Drugs Target Rare, Hard-to-Treat Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc.’s Stars are led by HETLIOZ, Fanapt LAI, Tradipitant, VTR-297, and VQW-765 because each sits in a niche with strong unmet need and pricing power. HETLIOZ serves a rare disorder affecting about 50% to 80% of totally blind people, while CNS and oncology assets can scale in larger pools. Success in late-stage data is the key trigger.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar case\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHETLIOZ\u003c\/td\u003e\n\u003ctd\u003eRare disease, premium pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFanapt LAI\u003c\/td\u003e\n\u003ctd\u003eAdherence gap, CNS growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTradipitant\u003c\/td\u003e\n\u003ctd\u003eFew GI options, late-stage upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eVanda Pharmaceuticals’ BCG Matrix maps its drugs by growth and market share, highlighting invest, hold, or divest priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Vanda Pharmaceuticals, instantly showing each business unit’s quadrant and strategic priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Vanda Pharmaceuticals Inc., making key claims easier to verify and decisions easier to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHETLIOZ non-24 oral capsules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHETLIOZ non-24 oral capsules are a classic cash cow for Vanda Pharmaceuticals Inc.: the core 20 mg oral dose is already approved and commercialized, so spending stays modest versus launch-stage drugs. Non-24 in totally blind adults is a rare, clinically defined market, which keeps promotion narrow and prescribing steady. Mature demand can keep producing cash instead of consuming it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFanapt oral tablets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFanapt oral tablets are approved for schizophrenia and sit in a mature oral antipsychotic market where repeat prescriptions drive steady demand. That makes the brand a low-spend, recurring cash generator for Vanda Pharmaceuticals Inc. In 2025, this kind of established product typically needs far less launch spend than new drugs, which fits the cash cow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 approved brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc. runs on 2 approved brands, Fanapt and Hetlioz, so its commercial base is narrow and easier to manage.\u003c\/p\u003e\n\u003cp\u003eThat small portfolio lowers selling and operating complexity, which helps protect margins while the brands stay mature.\u003c\/p\u003e\n\u003cp\u003eCash from these 2 products is best harvested, not pushed for fast growth, and it helps fund Vanda Pharmaceuticals Inc.’s pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS commercial sales base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUS commercial sales remain Vanda Pharmaceuticals Inc.'s main cash cow: domestic product sales are the company’s most mature channel and the biggest share of revenue. Strong payer access and brand recognition help keep cash generation efficient, while the business looks low growth and more about harvesting than expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMost established revenue engine\u003c\/li\u003e\n\u003cli\u003eStrong U.S. payer coverage\u003c\/li\u003e\n\u003cli\u003eHigh brand awareness supports demand\u003c\/li\u003e\n\u003cli\u003eLow-growth, cash-rich asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEurope and Israel sales base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVanda’s Europe and Israel sales base fits Cash Cows: approved products keep earning with little new-launch spend. In 2025, the company posted about $217.7 million in total net product sales, so these markets help extend the life of existing brands while keeping capital needs light.\u003c\/p\u003e\n\u003cp\u003eThat makes the region a harvest engine, not a hypergrowth bet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroadens reach without heavy launch costs\u003c\/li\u003e\n\u003cli\u003eSupports longer product life cycles\u003c\/li\u003e\n\u003cli\u003eCash generation over rapid expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVanda’s Cash Cows Keep Cash Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc.’s Cash Cows are Fanapt and Hetlioz: two approved, mature brands that need little launch spend and keep recurring cash flowing. In 2025, Vanda Pharmaceuticals Inc. reported about $217.7 million in total net product sales, showing a stable harvest base. U.S. sales and select ex-U.S. markets support this low-growth, cash-rich profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal net product sales\u003c\/td\u003e\n\u003ctd\u003e$217.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore cash cows\u003c\/td\u003e\n\u003ctd\u003eFanapt, Hetlioz\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVanda Pharmaceuticals Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Vanda Pharmaceuticals Inc. BCG Matrix document you’ll receive after purchase. No demo content or placeholders—just the final, fully formatted report. Once purchased, the same file is ready for download, editing, or presentation. It’s a clean, analysis-ready asset for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVHX-896 iloperidone metabolite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVHX-896 is the active metabolite of iloperidone, so it sits almost entirely inside the Fanapt franchise rather than opening a new market. That overlap makes it a clear Dogs case in Vanda Pharmaceuticals Inc.'s BCG Matrix. With no separate 2025 revenue stream and no disclosed standalone sales, its strategic value looks weak versus the core commercial asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBPO-27 secretory diarrhea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBPO-27 targets secretory diarrhea disorders, including cholera, but the market is episodic and tied to outbreaks, so demand can swing fast. Global cholera cases reported to WHO reached 535,000+ in 2024, yet this is still a narrow, event-driven market. That makes development economics weaker than Vanda Pharmaceuticals Inc.'s larger CNS or oncology bets, with low share and limited repeat revenue support, so it fits a dog-like asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCFTR dry-eye and ocular inflammation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc.'s CFTR activator and inhibitor set targets ocular disease, but dry eye and ocular inflammation are crowded arenas with many approved and pipeline rivals. Vanda has no proven commercial scale here yet, so the franchise stays in low-share territory. In BCG terms, that points to a Question Mark: high contest, no clear 2025\/2026 revenue base, and roughly 0% meaningful market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTradipitant atopic dermatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAtopic dermatitis is a crowded market, with roughly 10% to 20% of children and 2% to 10% of adults affected, so Tradipitant needs clear efficacy or safety edge to win. Without a sharp lead, share is hard to build, and that makes it a weak-fit Dogs asset in Vanda Pharmaceuticals Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetitive dermatology is hard to penetrate.\u003c\/li\u003e\n\u003cli\u003eDifferentiation must be obvious and durable.\u003c\/li\u003e\n\u003cli\u003eWeak share potential limits investment appeal.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy non-core preclinical set\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc.’s legacy preclinical set fits the Dog bucket because it sits outside the company’s core commercial engine and still burns R\u0026amp;D cash before any proof of value. In 2025, Vanda reported $150.4 million in revenue and $92.8 million in R\u0026amp;D expense, so even small early-stage programs can pressure returns if they do not move forward.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutside core sales base\u003c\/li\u003e\n\u003cli\u003eHigh cash burn before data\u003c\/li\u003e\n\u003cli\u003eFailed assets become sunk costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat is classic dog risk: low current value, uncertain odds, and capital tied up in programs that may never scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVanda’s Old Assets: High Cash Drain, No Revenue Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVHX-896, BPO-27, and Vanda Pharmaceuticals Inc.'s older preclinical assets all fit Dogs: low share, weak or episodic demand, and no clear 2025\/2026 revenue engine. Vanda Pharmaceuticals Inc. reported $150.4 million revenue and $92.8 million R\u0026amp;D in 2025, so these programs tie up cash without proven scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eVHX-896\u003c\/td\u003e\n\u003ctd\u003eNo standalone sales\u003c\/td\u003e\n\u003ctd\u003e0 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHETLIOZ Smith-Magenis syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHETLIOZ in Smith-Magenis syndrome is a Question Mark because it is a label-expansion play, not a mature market. Smith-Magenis syndrome is ultra-rare, affecting about 1 in 15,000 to 25,000 people, and remains underserved, so success could open a new revenue stream for Vanda Pharmaceuticals Inc. Until approval and uptake are proven, HETLIOZ’s share in this use case is still untested.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHETLIOZ pediatric Non-24\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHETLIOZ pediatric Non-24 is a BCG \"question mark\": the addressable pool is small, but the unmet need in blind children with Non-24 is real. The franchise could broaden if Vanda Pharmaceuticals Inc. wins more pediatric use, yet adoption stays uncertain because this niche needs physician awareness, payer support, and long follow-up. It will need more investment before it can become a meaningful revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFanapt bipolar disorder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFanapt in bipolar disorder is a classic question mark: the bipolar I market affects about 2.8% of U.S. adults each year, but Fanapt has proven sales only in schizophrenia. In Vanda Pharmaceuticals Inc.’s 2025 set-up, share in bipolar is still unproven, so the drug needs clear efficacy data and differentiation before it can win meaningful CNS revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTradipitant motion sickness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTradipitant for motion sickness sits in a broad, episodic-use market where a strong Phase 3 readout could drive quick uptake, but it still has no established share and no disclosed 2025 revenue. The bet is high risk, because adoption would depend on clear efficacy, clean safety, and a fast launch. If it works, the addressable use case is large and repeatable.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad episodic-use market\u003c\/li\u003e\n\u003cli\u003eNo established share yet\u003c\/li\u003e\n\u003cli\u003eFast uptake if efficacy is strong\u003c\/li\u003e\n\u003cli\u003eHigh-risk growth bet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJet lag disorder expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJet lag disorder expansion sits in a larger travel sleep market, but Vanda Pharmaceuticals Inc. must turn HETLIOZ’s known melatonin-pathway mechanism into new demand. The idea is growth-led, yet it is still unproven because success depends on regulatory wins and real-world adoption.\u003c\/p\u003e\n\u003cp\u003eUntil that happens, it remains a question mark in the BCG matrix: attractive upside, weak current proof. One clear signal: the jet lag use case is far bigger than HETLIOZ’s current narrow base, but it has not yet translated into approved revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge travel-linked sleep market\u003c\/li\u003e\n\u003cli\u003eMechanism is known, demand is not\u003c\/li\u003e\n\u003cli\u003eUpside depends on approval\u003c\/li\u003e\n\u003cli\u003eStill a question mark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVanda’s 2025 Upside Hinges on Three Unproven Growth Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVanda Pharmaceuticals Inc.’s question marks are HETLIOZ in Smith-Magenis syndrome and pediatric Non-24, Fanapt in bipolar disorder, and tradipitant or jet lag expansion: each has real demand, but 2025 share and revenue proof are still thin. The upside is clear, but each program still needs clinical, regulatory, and payer wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003cth\u003eWhy a question mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHETLIOZ SMS\u003c\/td\u003e\n\u003ctd\u003eUnproven\u003c\/td\u003e\n\u003ctd\u003eLabel expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFanapt bipolar\u003c\/td\u003e\n\u003ctd\u003eUnproven\u003c\/td\u003e\n\u003ctd\u003eNo share yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTradipitant\u003c\/td\u003e\n\u003ctd\u003eNo revenue\u003c\/td\u003e\n\u003ctd\u003eLaunch risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235131564297,"sku":"vnda-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vnda-bcg-matrix.webp?v=1785735471","url":"https:\/\/dcfanalyst.com\/products\/vnda-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}